Criticism mounts of India's 'abrupt' approval of local vaccine

Published January 6, 2021
A volunteer is seen during a dry run or a mock drill for the Covid-19 coronavirus vaccine, at a private hospital in Allahabad on January 5. — AFP
A volunteer is seen during a dry run or a mock drill for the Covid-19 coronavirus vaccine, at a private hospital in Allahabad on January 5. — AFP

Criticism of India's approval of a local Covid-19 vaccine without proof of its efficacy grew on Wednesday after news that a regulatory panel approved the shot just one day after asking the vaccine maker for more evidence it would work.

The recommendations of the Indian drug regulator's Subject Expert Committee (SEC) released on Tuesday show that the panel asked Bharat Biotech International Ltd to present more efficacy data for its Covid-19 shot before it could consider approving the treatment.

“After detailed deliberation, the committee recommended that the firm [...] may perform interim efficacy analysis for further consideration of restricted emergency use approval,” the SEC's recommendations in a Jan 1 meeting show.

The very next day, the committee recommended approving Bharat Biotech's vaccine for “restricted use in [an] emergency situation in public interest as an abundant precaution”.

The SEC also separately recommended emergency use authorisation for the Oxford University/AstraZeneca Covid-19 vaccine, being produced by India's Serum Institute.

The greenlighting of Bharat Biotech's Covaxin had already faced criticism from opposition lawmakers and health experts for lack of efficacy data, typically obtained from a large, Phase III human trial — which the manufacturer is still conducting.

News of the SEC's recommendations spurred further criticism.

“Was the Subject Expert Committee's (SEC) approval a command performance? This is as serious as it can get,” Manish Tewari, an opposition lawmaker, said on Twitter.

Health experts questioned why the SEC abruptly recommended approval one day after asking Bharat Biotech for more analysis.

“The SEC [...] appears to have been pressured overnight into reconsidering its decision and giving approval the next day, albeit hedged in by many conditions,” the All India People's Science Network, a network of science advocacy groups, said in a statement.

“We are perplexed at the abrupt change in thinking of the SEC from the first two meetings to the third day on which the approval was recommended while apparently discounting the need for efficacy data as the condition of the approval,” the All India Drug Action Network, a non-profit health watchdog, said.

Both Bharat Biotech and government officials have pointed to regulatory provisions that allow for quick drug approval for serious diseases even without Phase III trial data.

Neither India's drugs regulator nor Bharat Biotech responded to Reuters requests for comment on Wednesday.

Regulators also granted approval to Bharat Biotech's vaccine only “in clinical trial mode”, unusually cryptic language that left some experts baffled.

“They've introduced terminologies that are confusing,” said Giridhar Babu, a professor of epidemiology at the Public Health Foundation of India.

“The phrase 'in clinical trial mode' is not generally a term you will see in approvals.”

Any confusion around vaccines could harm immunisation programmes by causing distrust, Babu said. “It takes decades of work to build confidence in vaccines.”

[2]:

Opinion

Is it child abuse?
24 Sep 2021

Is it child abuse?

The SNC’s language mix doesn’t address our children’s emotional needs.
The gathering storm
Updated 24 Sep 2021

The gathering storm

The growing US-China rivalry has transformed the geopolitical scene, in particular the Asian strategic landscape.
New realities and challenges
Updated 23 Sep 2021

New realities and challenges

Will the Afghan Taliban entrust to the UN the responsibility of receiving and disbursing all aid?

Editorial

24 Sep 2021

Costs of growth

IS Pakistan’s growth party over? Not yet. But both the State Bank and government are now cutting down on the items...
Smear campaign
Updated 24 Sep 2021

Smear campaign

It is commendable that the government has taken the matter as seriously as it has, and delved deep into cyber investigations.
24 Sep 2021

Rising dengue cases

THE dengue monster is once again rearing its head in different cities of Punjab. More than 820 cases have surfaced ...
Dialogue, at last
Updated 23 Sep 2021

Dialogue, at last

The govt has attempted to make the ECP controversial at a time when its input is critical for the poll reforms
AUKUS controversy
Updated 23 Sep 2021

AUKUS controversy

Instead of flexing its military muscle, the Western bloc needs to engage China at the negotiating table.
Provocative act
Updated 23 Sep 2021

Provocative act

Afghan Taliban flags have been found hoisted at Jamia Hafsa seminary three times since Aug 21.